AbbVievs.Bristol Myers Squibb
ABBV vs BMY · both in Big pharma, part of the Medicine, pharma & life science value chain: Large, diversified pharmaceutical groups with broad portfolios across therapeutic areas.
AbbVie is about 4.0× larger than Bristol Myers Squibb by market cap; Bristol Myers Squibb trades at the lower P/E (13.0 vs 76.0); year to date, AbbVie leads (+18.8% vs +10.7%).
Side by side
| ABBV | BMY | |
|---|---|---|
| Market cap | $480B | $121B |
| Price | $272.42 | $59.58 |
| Today | +0.4% | −0.2% |
| Return YTD | +18.8% | +10.7% |
| Return 1Y | +16.5% | +33.7% |
| Since June 26, 2026 | +7.5% | +3.6% |
| P/E | 76.0 | 13.0 |
| P/S | 7.4 | 2.5 |
| P/B | 337.7 | 5.4 |
Data as of 2026-10-08 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
AbbVieABBV
Skyrizi and Rinvoq carry the immunology franchise. Oncology and neuroscience follow, plus the aesthetics business built around Botox.
Full ABBV profile →Bristol Myers SquibbBMY
Opdivo made the company's name in oncology. Immunology and haematology fill out the portfolio, with neuroscience coming through the pipeline.
Full BMY profile →More ABBV & BMY comparisons
Other head-to-heads in the Big pharma segment.